We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety.
- Authors
Samer, C F; Daali, Y; Wagner, M; Hopfgartner, G; Eap, C B; Rebsamen, M C; Rossier, M F; Hochstrasser, D; Dayer, P; Desmeules, J A
- Abstract
The major drug-metabolizing enzymes for the oxidation of oxycodone are CYP2D6 and CYP3A. A high interindividual variability in the activity of these enzymes because of genetic polymorphisms and/or drug-drug interactions is well established. The possible role of an active metabolite in the pharmacodynamics of oxycodone has been questioned and the importance of CYP3A-mediated effects on the pharmacokinetics and pharmacodynamics of oxycodone has been poorly explored.
- Publication
British journal of pharmacology, 2010, Vol 160, Issue 4, p919
- ISSN
1476-5381
- Publication type
Journal Article
- DOI
10.1111/j.1476-5381.2010.00709.x